Genmab intends to acquire all the shares of Merus and its late-stage, first-in-class cancer drug petosemtamab for approximately $8 billion. Petosemtamab, with pembrolizumab, is in Phase III development for head and neck squamous cell (HNSCC) and has two breakthrough therapy designations. The drug is a human, common light chain, IgG1 bispecific antibody targeting EGFR and LGR5 and developed on Merus’ proprietary Multiclonics platform.

Genmab expects this acquisition will help shift the company to a wholly owned model, expanding and diversifying its revenue and driving sustained growth into the next decade. In a press release , Genmab said it sees petosemtamab, Merus’ lead asset, as a compelling strategic fit with Genmab’s portfolio that aligns with Genmab’s expertise in antibody ther

See Full Page